There are currently 121 ongoing clinical trials involving Amyotrophic Lateral Sclerosis
Of the 121 trials,49 trials are in Phase II
Furthermore, 24 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Amyotrophic Lateral Sclerosis, a Central Nervous System disorder. The highest number of ongoing clinical trials involving Amyotrophic Lateral Sclerosis is in North America. Europe and Asia-Pacific are among some of the other prominent regions involved in Amyotrophic Lateral Sclerosis-related drug trials.
Biogen Inc: The leading ongoing Amyotrophic Lateral Sclerosis-related clinical trials sponsor
Biogen Inc, the United States of America-based pharmaceutical company, is the top sponsor for Amyotrophic Lateral Sclerosis-related ongoing clinical trials.
Amylyx Pharmaceuticals Inc, Collaborative Medicinal Development LLC, Mitsubishi Tanabe Pharma Corp, Azienda Ospedaliero-Universitaria di Modena, and Massachusetts General Hospital are a few other notable sponsors involving Amyotrophic Lateral Sclerosis.
A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Amyotrophic Lateral Sclerosis
Edaravone (Radicut, MCI-186, Radicava), Riluzole, and Riluzole (Exservan) are among the key marketed drugs involving Amyotrophic Lateral Sclerosis.
Edaravone (Radicut, MCI-186, Radicava) is a neuroprotective agent acts as free radical scavenger. It functions via the Free Radical Scavenger mechanism of action. It is formulated as an injectable solution for intravenous/ intravenous drip route of administration and suspension for the oral route. Radicut improves nerve symptoms associated with acute cerebral infarction. It is also indicated for the treatment of amyotrophic lateral sclerosis (ALS).Edaravone was first approved in 2001 and is marketed globally including the US, Canada, South Korea, China, and Japan by several prominent pharma giants including Mitsubishi Tanabe Pharma Corp.
Riluzole is a benzothiazole derivative that acts as a neuroprotective agent, belongs to central nervous system agents. It functions via the Glutamate Ionotropic Receptor (GRI) Antagonist; Voltage-Gated Sodium Channel (SCN) Blocker mechanism of action. It is formulated as film-coated tablets for the oral route of administration. Riluzole is indicated for patients with amyotrophic lateral sclerosis (ALS) and suppression of disease progression of amyotrophic lateral sclerosis (ALS). Riluzole was first approved in 2013 and is marketed in Japan by several prominent pharma giants including Takeda Pharmaceutical Co Ltd.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer